AURIZON EAR DROPS, SUSPENSION

Šalis: Airija

kalba: anglų

Šaltinis: HPRA (Health Products Regulatory Authority)

Nusipirk tai dabar

Parsisiųsti Prekės savybės (SPC)
10-05-2017

Veiklioji medžiaga:

MARBOFLOXACIN, CLOTRIMAZOLE, DEXAMETHASONE (AS DEXAMETHASONE ACETATE)

Prieinama:

Vetoquinol UK Limited

ATC kodas:

QS02CA06

INN (Tarptautinis Pavadinimas):

MARBOFLOXACIN, CLOTRIMAZOLE, DEXAMETHASONE (AS DEXAMETHASONE ACETATE)

Dozė:

Unknown

Vaisto forma:

Ear Drops Suspension

Recepto tipas:

POM

Farmakoterapinė grupė:

Canine

Gydymo sritis:

Dexamethasone and antiinfectives

Terapinės indikacijos:

Antibacterial

Autorizacija statusas:

Authorised

Leidimo data:

2016-03-24

Prekės savybės

                                SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
AURIZON ear drops, suspension
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
1 ML OF AURIZON CONTAINS:
For a full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Ear drops, suspension
Homogenous beige to yellow oily suspension
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
-
Treatment
of
otitis
externa of
both bacterial
and fungal
origin -
respectively due to bacteria sensitive to
marbofloxacin, and fungi especially_ Malassezia pachydermatis_
sensitive to clotrimazole.
The product should be used based on susceptibility testing.
4.3 CONTRAINDICATIONS
Do not
administer to dogs suffering from perforation of the tympanic
membrane.
Do not
administer to dogs with
known hypersensitivity to any of the ingredients.
Do not administer to pregnant or lactating bitches.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
ACTIVE SUBSTANCES:
Marbofloxacin
3.0
mg
Clotrimazole
10.0 mg
Dexamethasone acetate
1.0
mg
(equivalent to dexamethasone 0.9
mg)
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
_D_
_a_
_t_
_e_
_ _
_P_
_r_
_i_
_n_
_t_
_e_
_d_
_ _
_2_
_5_
_/_
_0_
_4_
_/_
_2_
_0_
_1_
_7_
_C_
_R_
_N_
_ _
_7_
_0_
_2_
_6_
_1_
_3_
_3_
_p_
_a_
_g_
_e_
_ _
_n_
_u_
_m_
_b_
_e_
_r_
_:_
_ _
_1_
4.5 SPECIAL PRECAUTIONS FOR USE
I) SPECIAL PRECAUTIONS FOR USE IN ANIMALS
Heavy reliance on a single class of antibiotic may result in the
induction of resistance in a bacterial population.
It is
prudent to reserve the fluoroquinolo
                                
                                Perskaitykite visą dokumentą
                                
                            

Peržiūrėti dokumentų istoriją